https://www.selleckchem.com/pr....oducts/jh-x-119-01.h
An extrapolated hippocampal volume based on body weight was not possible in this study population. In the CaLIPSO study, intravenous administration of SNF472 (300 or 600 mg) during hemodialysis significantly attenuated progression of coronary artery and aortic valve calcification. SNF472 selectively inhibits formation of hydroxyapatite, the final step in cardiovascular calcification. Because bone mineral is predominantly hydroxyapatite, we assessed changes in bone mineral density in CaLIPSO. Patients with coronary artery calcificati
Like
Comment
Share
